Market closed
Sight Sciences/$SGHT
13:30
15:10
16:45
18:25
20:00
1D1W1MYTD1Y5YMAX
About Sight Sciences
Sight Sciences Inc is an ophthalmic medical device company focused on the development and commercialization of surgical and nonsurgical technologies for the treatment of prevalent eye diseases. Its Surgical Glaucoma segment's product portfolio features the OMNI Surgical System, a device that facilitates the performance of both canaloplasty and trabeculotomy with a single device and single corneal incision to reduce intraocular pressure in adult patients with primary open-angle glaucoma. The company's Dry Eye segment's product portfolio consists of the TearCare System for ophthalmologists and optometrists. It derives key revenue from the Surgical Glaucoma segment.
Ticker
$SGHT
Sector
Trading on
Industry
Health Care Equipment & Supplies
Headquarters
Employees
216
Website
Sight Sciences Metrics
BasicAdvanced
$137M
-
-$1.03
2.51
-
Price and volume
Market cap
$137M
Beta
2.51
52-week high
$8.45
52-week low
$2.17
Average daily volume
304K
Financial strength
Current ratio
9.036
Quick ratio
8.478
Long term debt to equity
44.966
Total debt to equity
44.966
Interest coverage (TTM)
-10.84%
Management effectiveness
Return on assets (TTM)
-20.41%
Return on equity (TTM)
-49.59%
Valuation
Price to revenue (TTM)
1.679
Price to book
1.56
Price to tangible book (TTM)
1.56
Price to free cash flow (TTM)
-5.899
Growth
Revenue change (TTM)
-1.47%
Earnings per share change (TTM)
-10.06%
3-year revenue growth (CAGR)
17.72%
3-year earnings per share growth (CAGR)
-24.16%
What the Analysts think about Sight Sciences
Analyst Ratings
Analyst ratings (Buy, Hold, Sell) for Sight Sciences stock.
Sight Sciences Financial Performance
Income Statement
Revenues and expenses
QuarterlyAnnual
Q3 24
QoQ growth
Revenue
$37B
-39.75%
Net income
$45B
107.52%
Profit margin
37.65%
6.78%
Sight Sciences Earnings Performance
Earnings per share (EPS)
Company profitability
QuarterlyAnnual
Q4 23
Q1 24
Q2 24
Q3 24
Q4 24
Actual
$3.69
$2.85
$2.45
$2.42
-
Expected
$3.55
$2.61
$2.05
$2.31
$3.94
Surprise
3.94%
9.20%
19.51%
4.63%
-
Sight Sciences News
AllArticlesVideos
Sight Sciences to Present at the 24th Annual Needham Healthcare Conference on April 8th
GlobeNewsWire·2 days ago
Sight Sciences, Inc. (SGHT) Q4 2024 Earnings Conference Call Transcript
Seeking Alpha·3 weeks ago
Sight Sciences Reports Fourth Quarter and Full Year 2024 Financial Results and Initiates Full Year 2025 Financial Guidance
GlobeNewsWire·3 weeks ago
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real time US market data is a consolidated feed of IEX, NYSE National, NYSE Chicago, Nasdaq BX and Nasdaq PSX order books provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.
FAQs
What’s the current market cap for Sight Sciences stock?
Sight Sciences (SGHT) has a market cap of $137M as of March 28, 2025.
What is the P/E ratio for Sight Sciences stock?
The price to earnings (P/E) ratio for Sight Sciences (SGHT) stock is 0 as of March 28, 2025.
Does Sight Sciences stock pay dividends?
No, Sight Sciences (SGHT) stock does not pay dividends to its shareholders as of March 28, 2025.
When is the next Sight Sciences dividend payment date?
Sight Sciences (SGHT) stock does not pay dividends to its shareholders.
What is the beta indicator for Sight Sciences?
Sight Sciences (SGHT) has a beta rating of 2.51. This means that it is more volatile than the market, on average. A beta of 1 would indicate the stock moves in-line with the market, while a beta of 2 would indicate the stock moves twice as much as the market.